All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Psoriasis, a chronic inflammatory skin disease, affects up to 8.5% of adult populations \[[@pone.0173981.ref001]\]. Psoriasis was previously considered a solely cutaneous entity but recent studies, including a meta-analysis, have shown that moderate-to-severe psoriasis patients have increased cardiovascular risk, with more frequent atherosclerotic events (ex. myocardial infarction) and life expectancy reduction by up to 4 years \[[@pone.0173981.ref002]--[@pone.0173981.ref004]\]. Although one study showed no link between psoriasis and cardiovascular morbidity \[[@pone.0173981.ref005]\], data in the literature predominantly demonstrates that an association exists.

Interleukin-1alpha (IL-1α) \[[@pone.0173981.ref006], [@pone.0173981.ref007]\] and interleukin-1beta (IL-1β) \[[@pone.0173981.ref008]\], the two major subunits of IL-1, are implicated in psoriasis pathogenesis. Increased expression of IL-1α and IL-1β have been found in psoriatic lesional skin in mouse models and in human subjects, as these cytokines directly contribute to the inflammation present in the skin \[[@pone.0173981.ref006], [@pone.0173981.ref008], [@pone.0173981.ref009]\]. However, inflammation in psoriasis is not confined to skin; evidence of chronic systemic inflammation exists \[[@pone.0173981.ref010]\]. The systemic inflammatory milieu in psoriasis likely contributes to the atherosclerosis (considered an inflammatory disease) present in this disease \[[@pone.0173981.ref011]\]. Specifically, increased levels of IL-1 have been found in this systemic inflammatory milieu \[[@pone.0173981.ref012]\]. Since IL-1α and IL-1β have been shown to contribute to vascular inflammation and atherosclerosis \[[@pone.0173981.ref013]--[@pone.0173981.ref015]\], the increased levels of serum IL-1 noted in psoriasis may be responsible for promoting atherosclerosis.

Diacerein is an IL-1 inhibitor, approved in Europe as an oral anti-inflammatory treatment for osteoarthritis. The aim of this study is to investigate IL-1-driven regulation of genes related to inflammation and atherogenesis in human coronary artery endothelial cells (EC) and keratinocytes (KC), and to study the effects of diacerein on this gene regulation. ECs and KCs were utilized because they are directly involved in atherogenesis and psoriasis pathogenesis, respectively \[[@pone.0173981.ref008], [@pone.0173981.ref016]\].

Results {#sec002}
=======

In endothelial cells treated with IL-1α {#sec003}
---------------------------------------

PCR-Array: mRNA expression of 16 of 84 atherosclerosis-related genes were significantly regulated at least 2-fold by IL-1α alone in comparison to control (p\<.05), ranging from 8.3-fold (SELPLG) to 108.4-fold (TGFB2) up-regulation. Other genes regulated include ACE, BCL2L1, CSF2, FAS, ICAM1, LIF, MMP1, NR1H3, PLIN2, PPARG, SELE, ITGA2, TGFB1 and TNFAIP3. Adding 15µM diacerein partially or completely reversed these regulations in 15 of the 16 genes (**[Table 1](#pone.0173981.t001){ref-type="table"}**). Real-time PCR verified the PCR-Array results of IL-1-induced regulation and their reversal by diacerein for ICAM1 and SELE (these and other real-time PCR data not shown).

10.1371/journal.pone.0173981.t001

###### Atherosclerosis PCR-array: genes regulated by IL-1α and diacerein in ECs[^1^](#t001fn001){ref-type="table-fn"}

![](pone.0173981.t001){#pone.0173981.t001g}

  Refseq      Symbol    Name/description of gene                                                 mRNA fold-regulation, with IL-1α only   mRNA fold-regulation, with IL-1α + 15μM diacerein
  ----------- --------- ------------------------------------------------------------------------ --------------------------------------- ---------------------------------------------------
  NM_000789   ACE       Angiotensin I converting enzyme 1                                        52.0382                                 -3.5599
  NM_000633   BCL2L1    BCL2-like 1                                                              12.9257                                 -1.3853
  NM_000758   CSF2      Colony stimulating factor 2 (granulocyte-macrophage)                     -84.2634                                -7.2828
  NM_000043   FAS       Fas (TNF receptor superfamily, member 6)                                 72.9667                                 5.6288
  NM_000201   ICAM1     Intercellular adhesion molecule 1                                        39.2105                                 6.0664
  NM_002203   ITGA2     Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)             8.7675                                  2.5589
  NM_002309   LIF       Leukemia inhibitory factor (cholinergic differentiation factor)          43.1298                                 73.4064
  NM_002421   MMP1      Matrix metallopeptidase/metalloproteinase 1 (interstitial collagenase)   22.9141                                 2.2828
  NM_005693   NR1H3     Nuclear receptor subfamily 1, group H, member 3                          13.7768                                 -1.8928
  NM_001122   PLIN2     Perilipin 2                                                              12.6597                                 -1.0402
  NM_015869   PPARG     Peroxisome proliferator-activated receptor gamma                         19.6415                                 -3.1847
  NM_000450   SELE      Selectin E                                                               15.8363                                 1.6804
  NM_003006   SELPLG    Selectin P ligand                                                        8.3349                                  -3.1635
  NM_000660   TGFB1     Transforming growth factor, beta 1                                       28.664                                  2.9509
  NM_003238   TGFB2     Transforming growth factor, beta 2                                       108.3709                                6.0987
  NM_006290   TNFAIP3   Tumor necrosis factor, alpha-induced protein 3                           -2.1267                                 2.7613

1\. All mRNA fold regulations are in comparison to control. These 16 genes were significantly regulated at least 2-fold by IL-1α (p\<.05). 15µM -diacerein treatment reversed the effect of IL-1α in 15 genes, excepting LIF.

ELISA: quantitative protein expression of ACE, SELE and TGFB2 confirmed their up-regulation found on the mRNA level. Diacerein reversed IL-1α-induced protein up-regulation of these 3 genes. (**[Fig 1](#pone.0173981.g001){ref-type="fig"}**)

![Regulation of genes at protein levels with IL-1α and diacerein in ECs.\
Protein expression by ELISA of TGF-B2, ACE, and SELE. Human endothelial cells were treated for 24 hours with IL-1α and diacerein as described in Methods. Cell culture supernatant was measured by ELISA assays according to the manufacturer's instructions. Values are expressed as the mean ± SEM (*n* = 4). \**P* \< 0.05 *vs*. control.](pone.0173981.g001){#pone.0173981.g001}

In endothelial cells treated with IL-1β {#sec004}
---------------------------------------

PCR-Array: mRNA expression of 18 of 84 atherosclerosis-related genes were significantly regulated at least 2-fold by IL-1β alone in comparison to control (p\<.05), ranging from 2.3-fold (LDLR) to 1378.9-fold (CSF2) up-regulation. Other genes regulated include BCL2A1, BIRC3, CCL2, CCL5, CD44, CSF1, ICAM1, IL1A, NFKB1, SELE, SELL, SERPINB2, TNC, TNF, TNFAIP3 and VCAM1. Adding 50µM diacerein partially or completely reversed these regulations in all 18 genes (**[Table 2](#pone.0173981.t002){ref-type="table"}**)

10.1371/journal.pone.0173981.t002

###### Atherosclerosis PCR-array: genes regulated by IL-1β and diacerein in ECs[^1^](#t002fn001){ref-type="table-fn"}

![](pone.0173981.t002){#pone.0173981.t002g}

  Refseq      Symbol     Name/description of gene                                               mRNA fold-regulation, with IL-1β only   mRNA fold-regulation, with IL-1β + 50μM Diacerein
  ----------- ---------- ---------------------------------------------------------------------- --------------------------------------- ---------------------------------------------------
  NM_004049   BCL2A1     BCL2-related protein A1                                                13.7129                                 3.5032
  NM_001165   BIRC3      Baculoviral IAP repeat containing 3                                    9.4625                                  2.2038
  NM_002982   CCL2       Chemokine (C-C motif) ligand 2                                         3.8626                                  1.4233
  NM_002985   CCL5       Chemokine (C-C motif) ligand 5                                         24.6279                                 12.0685
  NM_000610   CD44       CD44 molecule (Indian blood group)                                     4.3224                                  1.9634
  NM_000757   CSF1       Colony stimulating factor 1 (macrophage)                               5.0849                                  1.4718
  NM_000758   CSF2       Colony stimulating factor 2 (granulocyte-macrophage)                   1378.9153                               64.44
  NM_000201   ICAM1      Intercellular adhesion molecule 1                                      9.4378                                  4.5319
  NM_000575   IL1A       Interleukin 1, alpha                                                   8.2156                                  3.0368
  NM_000527   LDLR       Low density lipoprotein receptor                                       2.363                                   1.5953
  NM_003998   NFKB1      Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1   3.5548                                  1.3165
  NM_000450   SELE       Selectin E                                                             60.2549                                 11.0446
  NM_000655   SELL       Selectin L                                                             3.4971                                  -2.244
  NM_002575   SERPINB2   Serpin peptidase inhibitor, clade B (ovalbumin), member 2              2.4898                                  1.6138
  NM_002160   TNC        Tenascin C                                                             78.3031                                 2.5861
  NM_000594   TNF        Tumor necrosis factor                                                  55.4908                                 1.3097
  NM_006290   TNFAIP3    Tumor necrosis factor, alpha-induced protein 3                         10.591                                  6.3517
  NM_001078   VCAM1      Vascular cell adhesion molecule 1                                      5.7961                                  -2.1991

1\. All mRNA fold regulations are in comparison to control. These 18 genes were significantly regulated at least 2-fold by IL-1β (p\<.05). 50µM -diacerein treatment reversed the effect of IL-1β in all 18 genes.

ELISA: quantitative protein expression of SELE, VCAM1, CSF2, TNF and CCL5 confirmed their up-regulation found on the mRNA level. Diacerein reversed IL-1β-induced protein up-regulation of these 5 genes. (**[Fig 2](#pone.0173981.g002){ref-type="fig"}**)

![Regulation of genes at the protein level with IL-1β and diacerein in ECs.\
Protein expression by ELISA of SELE, VCAM1, CSF2, TNF-alpha, and CCL5. Human primary keratinocytes were treated for 24 hours with IL-1β and diacerein as described in Methods. Cell culture supernatant was measured by ELISA assays according to the manufacturer's instructions. Values are expressed as the mean ± SEM (*n* = 4). \**P* \< 0.05 *vs*. control.](pone.0173981.g002){#pone.0173981.g002}

In keratinocytes treated with IL-1α {#sec005}
-----------------------------------

PCR-Array: mRNA expression of 24 of 370 inflammation-related genes were significantly regulated at least 2-fold by IL-1α alone in comparison to control (p\<.05), ranging from 2.1-fold (CCL20) to 377.2-fold (IL-9) up-regulation. Other genes regulated include C3, CCL20, CSF2, CSF3, CXCL2, CXCL3, CXCL6, CXCR3, IL17C, IL17RB, IL23A, IL36G, IL9, ITGB2, NAMPT, NOX5, PTAFR, S100A8, SERPINA3, SPRED1, TNFSF10, and TNFSF18. Adding 10µM diacerein partially or completely reversed these regulations in all 24 genes (**[Table 3](#pone.0173981.t003){ref-type="table"}**). Real-time PCR verified the PCR-Array results of IL-1-induced regulation and their reversal by diacerein for CXCL2.

10.1371/journal.pone.0173981.t003

###### Inflammation PCR-array: genes regulated by IL-1α and diacerein in KCs[^1^](#t003fn001){ref-type="table-fn"}

![](pone.0173981.t003){#pone.0173981.t003g}

  Refseq      Symbol      Name/description of gene                                                              mRNA fold-regulation, with IL-1α only   mRNA fold-regulation, with IL-1α + 10μM diacerein
  ----------- ----------- ------------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------------------
  NM_001719   BMP7        Bone morphogenetic protein 7                                                          15.1002                                 2.0256
  NM_000064   C3          Complement component 3                                                                38.5144                                 -2.0974
  NM_004591   CCL20       Chemokine (C-C motif) ligand 20                                                       2.1197                                  -2.3636
  NM_000758   CSF2        Colony stimulating factor 2 (granulocyte-macrophage)                                  3.8322                                  1.426
  NM_000759   CSF3        Colony stimulating factor 3 (granulocyte)                                             5.9347                                  3.9513
  NM_002089   CXCL2       Chemokine (C-X-C motif) ligand 2                                                      4.9058                                  1.3513
  NM_002090   CXCL3       Chemokine (C-X-C motif) ligand 3                                                      4.8753                                  -1.0112
  NM_002993   **CXCL6**   Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2)                  3.5607                                  -5.1242
  NM_001504   CXCR3       Chemokine (C-X-C motif) receptor 3                                                    9.4556                                  1.5182
  NM_013278   IL17C       Interleukin 17C                                                                       4.7662                                  -1.4756
  NM_018725   IL17RB      Interleukin 17 receptor B                                                             4.3645                                  1.4634
  NM_016584   IL23A       Interleukin 23, alpha subunit p19                                                     20.452                                  3.0674
  NM_019618   IL36G       Interleukin 36, gamma                                                                 5.1964                                  3.0377
  NM_000590   IL9         Interleukin 9                                                                         377.2329                                1.9625
  NM_000211   ITGB2       Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)                    8.0995                                  5.3
  NM_005746   NAMPT       Nicotinamide phosphoribosyltransferase                                                3.555                                   2.051
  NM_024505   NOX5        NADPH oxidase, EF-hand calcium binding domain 5                                       5.3499                                  1.9234
  NM_000952   PTAFR       Platelet-activating factor receptor                                                   3.519                                   1.3278
  NM_002964   S100A8      S100 calcium binding protein A8                                                       3.5599                                  1.0497
  NM_001085   SERPINA3    Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3   7.3982                                  3.7974
  NM_152594   SPRED1      Sprouty-related, EVH1 domain containing 1                                             3.8884                                  1.8176
  NM_003265   TLR3        Toll-like receptor 3                                                                  3.2652                                  -23.5611
  NM_003810   TNFSF10     Tumor necrosis factor (ligand) superfamily, member 10                                 3.4818                                  -3.4271
  NM_005092   TNFSF18     Tumor necrosis factor (ligand) superfamily, member 18                                 31.3306                                 3.9068

1\. All mRNA fold regulations are in comparison to control. These 24 genes were significantly regulated at least 2-fold by IL-1α (p\<.05) 10µM -diacerein treatment reversed the effect of IL-1α in all 24 genes.

ELISA: quantitative protein expression of CXCR3, IL9 and CSF2 confirmed their up-regulation found on the mRNA level. Diacerein reversed IL-1α-induced protein regulation of these 3 genes. (**[Fig 3](#pone.0173981.g003){ref-type="fig"}**)

![Regulation of genes at protein levels with IL-1α and diacerein in KCs.\
Protein expression by ELISA of CXCR3, IL-9, CSF2. Human primary keratinocytes were treated for 24 hours with IL-1α and diacerein as described in Methods. Cell culture supernatant was measured by ELISA assays according to the manufacturer's instructions. Values are expressed as the mean ± SEM (*n* = 4). \**P* \< 0.05 *vs*. control.](pone.0173981.g003){#pone.0173981.g003}

In keratinocytes treated with IL-1β {#sec006}
-----------------------------------

PCR-Array: mRNA expression of 44 of 370 inflammation-related genes were significantly regulated at least 2-fold by IL-1β alone in comparison to control (p\<.05) ranging from 2.1-fold (HDAC9) to 70.9-fold (S100A8) up-regulation. Other genes regulated include CCL11, 20, 28, and 5, CXCL1, 2 and 6, GDF2, HDAC9, IL32, LIF, OLR1 and SYK (partial list). Adding 20µM diacerein partially or completely reversed these regulations in all 44 genes. (**[Table 4](#pone.0173981.t004){ref-type="table"}**)

10.1371/journal.pone.0173981.t004

###### Inflammation PCR-array: genes regulated by IL-1β and diacerein in KCs[^1^](#t004fn001){ref-type="table-fn"}

![](pone.0173981.t004){#pone.0173981.t004g}

  Refseq      Symbol     Name/description of gene                                    mRNA fold regulation, with IL-1β only   mRNA fold regulation, with IL-1β + 20μM diacerein
  ----------- ---------- ----------------------------------------------------------- --------------------------------------- ---------------------------------------------------
  NM_030882   APOL2      Apolipoprotein L, 2                                         2.3158                                  1.2406
  NM_000064   C3         Complement Comp 3                                           8.4772                                  3.6511
  NM_002986   CCL11      Chemokine ligand 11                                         2.5386                                  1.4083
  NM_004591   CCL20      Chemokine ligand 20                                         9.692                                   8.1897
  NM_148672   CCL28      Chemokine ligand 28                                         10.4915                                 3.19
  NM_002985   CCL5       Chemokine ligand 5                                          4.0996                                  3.127
  NM_016557   CCRL1      Chemokine receptor-like 1                                   2.5208                                  1.7298
  NM_000591   CD14       CD 14 molecule                                              5.5239                                  3.715
  NM_001242   CD27       CD 27 molecule                                              2.4294                                  1.3867
  NM_001250   CD40       CD 40 molecule                                              8.0095                                  3.5229
  NM_000759   CSF3       Colony stimulating factor 3 (granulocyte)                   4.3211                                  3.0818
  NM_001511   CXCL1      Chemokine CXC ligand 1                                      8.9677                                  1.8847
  NM_002089   CXCL2      Chemokine CXC ligand 2                                      10.719                                  2.5911
  NM_002993   CXCL6      Chemokine CXC 6                                             17.8413                                 1.8856
  NM_005755   EBI3       Epstein-Barr virus induced-3                                4.1834                                  2.5964
  NM_000799   EPO        Erythropoietin                                              6.7592                                  -22.9238
  NM_000132   F8         Coagulation factor VIII, procoagulant component             3.2593                                  1.7314
  NM_002026   FN1        Fibronectin 1                                               10.7261                                 9.5456
  NM_016204   GDF2       Growth differentiation factor 2                             2.503                                   -1.3364
  NM_000175   GPI        Glucose-6-phosphate isomerase                               4.2766                                  3.2351
  NM_013372   GREM1      Gremlin 1                                                   4.4034                                  2.8852
  NM_178425   HDAC9      Histone deacetylase 9                                       2.1274                                  1.5499
  NM_176891   IFNE       Interferon, epsilon                                         5.2112                                  2.1267
  NM_020124   IFNK       Interferon, kappa                                           3.2673                                  2.3779
  NM_000576   IL1B       Interleukin 1, beta                                         3.9408                                  3.1301
  NM_014432   IL20RA     Interleukin 20 receptor, alpha                              4.0027                                  1.153
  NM_004221   IL32       Interleukin 32                                              3.7943                                  1.9159
  NM_019618   IL36G      Interleukin 36, alpha                                       4.4501                                  3.9432
  NM_003994   KITLG      KIT ligand                                                  7.6168                                  4.9655
  NM_002309   LIF        Leukemia inhibitory factor                                  3.9508                                  2.1524
  NM_002349   LY75       Lymphocyte antigen 75                                       4.1975                                  -1.5135
  NM_002391   MDK        Midkine (neurite growth-promoting factor 2)                 5.0469                                  3.6923
  NM_002543   OLR1       Oxidized low density lipoprotein (lectin-like) receptor 1   2.5423                                  1.9627
  NM_006404   PROCR      Protein C receptor, endothelial                             5.1523                                  4.3059
  NM_018663   PXMP2      Peroxisomal membrane protein 2, 22kDa                       3.1204                                  2.0392
  NM_002964   S100A8     S100 calcium binding protein A8                             70.9305                                 28.5903
  NM_006512   SAA4       Serum amyloid A4, constitutive                              4.0531                                  2.4681
  NM_001085   SERPINA3   Serpin peptidase inhibitor, clade A                         15.5997                                 8.1322
  NM_003177   SYK        Spleen tyrosine kinase                                      4.9529                                  3.9094
  NM_003263   TLR1       Toll-like receptor 1                                        2.9755                                  1.1086
  NM_003265   TLR3       Toll-like receptor 3                                        4.0467                                  1.2142
  NM_006068   TLR6       Toll-like receptor 6                                        5.483                                   4.0153
  NM_000594   TNF        Tumor necrosis factor                                       10.0188                                 4.1693
  NM_003810   TNFSF10    Tumor necrosis factor (ligand) superfamily, member 10       18.1224                                 5.4619

1\. All mRNA fold regulations are in comparison to control. These 44 genes were significantly regulated at least 2-fold by IL-1β (p\<.05). 20µM diacerein treatment reversed the effect of IL-1β in all 44 genes.

Discussion {#sec007}
==========

Our results demonstrate that IL-1 acts as a pro-atherogenic and pro-inflammatory mediator in ECs and KCs. Addition of diacerein yielded complete or partial reversal of IL-1-induced gene regulation.

Endothelial cells {#sec008}
-----------------

### Diacerein reverses IL-1α-induced regulation of atherosclerosis-related genes in ECs ([Table 1](#pone.0173981.t001){ref-type="table"}) {#sec009}

IL-1α was found to be pro-atherogenic by regulating several genes in ECs including up-regulation of ACE, ICAM1and other genes; these regulations were reversed by diacerein, thus acting in an anti-atherogenic manner. ACE (angiotensin-1 converting enzyme) increases angiotensin-II, which elevates blood pressure. Elevated blood pressure accelerates atherogenesis \[[@pone.0173981.ref016]\] while angiotensin-II may independently promote vascular inflammation by increasing oxidative stress in vessel walls \[[@pone.0173981.ref017]\] ICAM1 (inter-cellular adhesion molecule-1) was also up-regulated by IL-1α in other studies \[[@pone.0173981.ref018], [@pone.0173981.ref019]\]. ICAM1, involved with inflammatory cell recruitment, was increased in atherosclerotic lesions \[[@pone.0173981.ref020]\]. Another study showed that reduced expression of cellular adhesion molecules in mice decreased atherogenicity \[[@pone.0173981.ref021]\]. Our IL-1α up-regulation of MMP1 (matrix metalloproteinase-1), was consistent with the findings of Hanemaaijer et al. \[[@pone.0173981.ref022]\] and was reversed by diacerein. MMP1 contributes to inflammatory cell intimal infiltration, plaque instability and rupture \[[@pone.0173981.ref023]\] and is correlated with increased total plaque burden \[[@pone.0173981.ref024]\]. Metalloproteinases are also implicated in multiple phases of atherosclerosis \[[@pone.0173981.ref025]\]. PLIN2 (perilipin-2), promoting foam-cell formation, was reported as a safe target for anti-atherogenic therapy \[[@pone.0173981.ref026]\]. SELE (E-selectin; facilitates vascular inflammatory cell infiltration) was up-regulated by IL-1α, consistent with Etter et al. \[[@pone.0173981.ref027]\]. We found diacerein significantly reduced EC protein expression of E-selectin, confirming functional down-regulation of the gene (**[Fig 1](#pone.0173981.g001){ref-type="fig"}**). E-selectin's importance to atherosclerosis was demonstrated in studies showing increased E-selectin on arterial plaque surfaces \[[@pone.0173981.ref028]\] and reduced development of atherosclerotic lesions in mice lacking SELE \[[@pone.0173981.ref029]\]. Diacerein also inhibited up-regulation of SELPLG (P-selectin ligand), which helps to recruit leukocytes to the endothelium \[[@pone.0173981.ref030]\].

Two genes were regulated in unique ways. TNFAIP3 (TNF-alpha-induced protein-3) was down-regulated by IL-1α, in contrast to genes discussed above. However IL-1α's effect was still pro-atherogenic because TNFAIP3 is reported to decrease inflammation and atherosclerosis in murine models \[[@pone.0173981.ref031]\]. Regarding LIF (leukemia inhibitory factor), two studies showed that its expression is inversely correlated with coronary atherosclerosis \[[@pone.0173981.ref032], [@pone.0173981.ref033]\]. We found IL-1α increased LIF expression, but diacerein further up-regulated the gene, enhancing LIF's anti-atherogenic correlation.

### Diacerein reverses IL-1β-induced regulation of atherosclerosis-related genes in ECs ([Table 2](#pone.0173981.t002){ref-type="table"}) {#sec010}

IL-1β was found to be pro-atherogenic by regulating several genes in ECs including up-regulating CCL2, CCL5and other genes; these were reversed by diacerein, thus acting in an anti-atherogenic manner. CCL2 and CCL5 (chemokines) promote vascular inflammation by attracting leukocytes to vessel walls. Additionally, CCL2 is absent in endothelium in normal conditions but is increased in the setting of atherosclerosis and associated with elevated risk of myocardial infarction \[[@pone.0173981.ref034]\]. CD44 and VCAM1 were up-regulated by IL-1β, in accordance with another report of IL-1β up-regulation of VCAM1 in ECs \[[@pone.0173981.ref035]\]. Both CD44 and VCAM1 recruit inflammatory cells to the endothelium, while CD44 also interacts with hyaluronan, a glycosaminoglycan increased in atherosclerotic lesions. CD44 and VCAM1 were increased in an atherosclerosis mouse-model too \[[@pone.0173981.ref036]\]. Interestingly, we found IL-1β up-regulated IL-1α in ECs; IL-1α is reported to be a strong facilitator of atherogenesis and a prospective therapeutic target to reduce vascular inflammation \[[@pone.0173981.ref014]\]. Thus, diacerein may reverse IL-1α's effects on atherosclerosis and also reduce its expression by ECs via suppressing IL-1β activity. TNC (tenascin-C), an extra-cellular matrix protein, is involved with induction of pro-inflammatory cytokines and metalloproteinases \[[@pone.0173981.ref037]\]. TNF (tumor necrosis factor-alpha), up-regulated by IL-1β in our study and another, \[[@pone.0173981.ref038]\] is thought to be pro-atherogenic by disrupting endothelial barrier function, inducing metalloproteinases and promoting vascular inflammation \[[@pone.0173981.ref039]\]. Diacerein reduced TNC and TNF protein expression by ECs (**[Fig 2](#pone.0173981.g002){ref-type="fig"}**).

### Other genes regulated in ECs with unclear links to atherosclerosis {#sec011}

CSF2 (granulocyte-macrophage colony-stimulating factor; recruits inflammatory cells) was down-regulated by IL-1α but highly up-regulated by IL-1β in ECs (including increased protein expression, **[Fig 2](#pone.0173981.g002){ref-type="fig"}**) and up-regulated by IL-1α in KCs. Given conflicting regulation of this gene, net effects that diacerein would exert on GM-CSF activity are unclear.

Although TGFB1 (transforming growth factor-beta1) and TGFB2 (transforming growth factor-beta2) were amplified within atherosclerotic plaques in one study \[[@pone.0173981.ref040]\], more convincing evidence indicates these proteins actually have an athero-protective effect \[[@pone.0173981.ref041]\]. Diacerein decreased TGFB1 and TGFB2 mRNA and protein expression in ECs, but only to levels that remained higher than those in untreated ECs (**[Fig 1](#pone.0173981.g001){ref-type="fig"}**). Thus, diacerein may not have great impact on atherogenesis through TGF-beta regulation.

Keratinocytes {#sec012}
-------------

KCs are clearly involved in psoriasis pathogenesis but unlike ECs, are not directly implicated in atherogenesis. However, gene regulation observed in KCs may still have implications for atherosclerosis in the following way. It has been suggested that the skin is a source of mediators that exert not only local inflammatory effects but also enter the circulation and cause systemic inflammation \[[@pone.0173981.ref042]\]; as discussed previously, systemic inflammation is associated with atherosclerosis. This may be one way skin inflammation leads to systemic and vascular inflammation, ultimately contributing to atherogenesis (**[Fig 4](#pone.0173981.g004){ref-type="fig"}**). Also, there may be a pro-inflammatory positive feedback-loop between the epidermis and endothelium which perpetuates this effect \[[@pone.0173981.ref006]\]. We found various inflammatory genes regulated by IL-1 in KCs, several of which may produce mediators that have atherogenic effects downstream in the vasculature. Diacerein reversed IL-1-induced regulation of all genes in KCs, thus acting in an anti-inflammatory and potentially anti-atherogenic manner.

![Proposed relationship of IL-1 with keratinocytes and endothelium.\
Increased levels of IL-1 locally in the skin and systemically in circulation lead to increase in pro-inflammatory and pro-atherogenic mediators in KCs and ECs. While these may have local effects in KCs leading to epidermal inflammation, they may also exert systemic effects by filtering into the circulation, ultimately leading to vascular inflammation downstream. The mediators produced by ECs promote atherogenesis as a local effect.](pone.0173981.g004){#pone.0173981.g004}

### Diacerein reverses IL-1α-induced regulation of genes linked to atherosclerosis in KCs ([Table 3](#pone.0173981.t003){ref-type="table"}) {#sec013}

IL-1α is potentially pro-atherogenic by regulating several genes in KCs; these regulations were reversed by diacerein. IL17C, a cytokine typically produced by Th17 cells, is the most plentiful IL-17 isoform in psoriatic lesions \[[@pone.0173981.ref006]\] and may stimulate cytokine production involved in vascular inflammation \[[@pone.0173981.ref043]\]. IL-23A is a cytokine that helps transform naïve CD4+ T-cells into Th17 cells, which as reported, may be pro-atherogenic \[[@pone.0173981.ref044], [@pone.0173981.ref045]\]. Serum IL-23 was also significantly elevated in patients with peripheral arterial disease, a manifestation of atherosclerosis \[[@pone.0173981.ref046]\]. Previous reports also showed IL-1 stimulates IL-17 and IL-23 production in T-cells \[[@pone.0173981.ref047], [@pone.0173981.ref048]\] Taken together, our data shows that IL-1α may increase Th17-mediated vascular inflammation.

IL-1α also up-regulated NOX5 in KCs, whose gene-product NADPH oxidase, stimulates production of reactive oxygen species (ROS). Dysregulation of this gene is implicated in cardiovascular disease and atherosclerosis secondary to ROS-induced vascular oxidative stress \[[@pone.0173981.ref049]--[@pone.0173981.ref051]\]. Zhong et al. also reported that rhein (diacerein metabolite) may protect against ROS-induced EC injury \[[@pone.0173981.ref052]\]. IL-9 mRNA and protein expression was considerably up-regulated by IL-1α (**[Fig 3](#pone.0173981.g003){ref-type="fig"}**). In a psoriasis mouse-model, IL-9 induced Th17-related inflammatory mediators \[[@pone.0173981.ref053]\]. Diacerein suppression of IL-9 may be anti-atherogenic by subsequently decreasing Th17-related activity. IL-1α also up-regulated NAMPT (visfatin), a pro-inflammatory cytokine elevated in psoriasis \[[@pone.0173981.ref054]\]. Visfatin circulating levels are correlated with clinical manifestations of atherosclerosis \[[@pone.0173981.ref055]\]. TNFSF18 (GITRL) is also up-regulated in KCs. Kim et al. found increased levels of GITRL's receptor, GITR, in atherosclerotic lesions, which when activated leads to metalloproteinase and pro-inflammatory cytokine production \[[@pone.0173981.ref056]\]. IL-1α-induced GITRL production by KCs may cause increased binding of GITR downstream. Diacerein also down-regulates several chemokines in KCs (CCL20, CXCL2, 3, and 6), and may oppose systemic inflammation in this way.

### Diacerein reverses IL-1β regulation of genes linked to atherosclerosis in KCs ([Table 4](#pone.0173981.t004){ref-type="table"}) {#sec014}

IL-1β is potentially pro-atherogenic by regulating several genes in KCs; these regulations were reversed by diacerein. CSF3 (granulocyte colony-stimulating factor), up-regulated by IL-1α and IL-1β, increased endothelin-1 and decreased nitric oxide synthase in an animal model, both of which are implicated in atherogenesis \[[@pone.0173981.ref057]\] BMP7 (bone-morphogenetic protein-7) and GDF2 (BMP9) were up-regulated by IL-1α and IL-1β, respectively. Inhibition of BMP-signaling, as diacerein provides, may impede atherosclerosis \[[@pone.0173981.ref058]\]. IL-1β up-regulated HDAC9; HDACs (histone deacetylases) are involved in atherogenesis and HDAC-inhibitors are a potential therapeutic target for cardiovascular disease \[[@pone.0173981.ref059]\]. IL-32 also is up-regulated in KCs by IL-1β; this cytokine may induce vascular inflammation and endothelial dysfunction \[[@pone.0173981.ref060]\]. OLR1 (Oxidized low-density lipoprotein receptor-1) is increased in atheromatous plaques, while serum levels of ORL1 are raised in coronary artery disease patients \[[@pone.0173981.ref061]\]. SYK (spleen tyrosine kinase) stimulates endothelin-1, implicated in atherogenesis \[[@pone.0173981.ref062]\]. Correspondingly, an SYK-inhibitor decreased atherogenesis in a mouse model \[[@pone.0173981.ref063]\]. Other genes regulated by IL-1β in KCs with potential links to atherosclerosis include CXCL1, Ebi3, IL-36G, CCL20, CCL11, PROCR, S100A8, MDK, IL20RA, CD40, IL-1β, IL36G, TLR1, TLR6 and LY75.

Diacerein reverses IL-1-induced gene regulation in KCs. By down-regulating factors from the skin that promote and sustain inflammation, diacerein may subsequently reduce circulating levels of inflammatory mediators.

### Diacerein and apoptosis {#sec015}

Diacerein was reported to induce or inhibitor apoptosis in different cell types \[[@pone.0173981.ref064]--[@pone.0173981.ref066]\]. Interestingly, there are reports that diacerein does not affect cell apoptosis \[[@pone.0173981.ref067], [@pone.0173981.ref068]\]. In our experimental setting, we found that diacerein inhibits apoptosis in keratinocytes while it has no role in endothelial cell apoptosis (**[Fig 5](#pone.0173981.g005){ref-type="fig"}**). The molecular mechanisms for diacerein's role in apoptosis of keratinocytes and endothelial cells need further investigation.

![Diacerein inhibits apoptosis in keratinocytes but not in endothelial cells.\
Primary KCs or ECs were treated with IL-1β (10ng/ml), diacerein (20 μM for KCs and 50 μm for ECs) or both for 24 hours. Apoptosis was measured by Pan-Caspase In Situ Assay Kit as described in Methods. Values are expressed as the mean ± SEM (n = 8). \* P \< 0.05 vs. control.](pone.0173981.g005){#pone.0173981.g005}

Conclusions {#sec016}
===========

Our results show that diacerein significantly opposes pro-atherogenic and pro-inflammatory effects of IL-1 on multiple genes in ECs and KCs. Psoriasis has increased IL-1 activity and increased risk of atherosclerosis and cardiovascular morbidity \[[@pone.0173981.ref003], [@pone.0173981.ref012]\]. Because our EC data and previous studies have demonstrated that IL-1α and IL-1β contribute to vascular inflammation/atherogenesis \[[@pone.0173981.ref013]--[@pone.0173981.ref015]\], the elevated activity of IL-1 in psoriasis may contribute to this increased risk of atherosclerosis. Additionally, our KC data show that diacerein may diminish skin inflammation but also may have potential implications for atherogenesis in psoriasis: diacerein inhibits IL-1-induced regulation of several inflammatory genes in KCs reported to have pro-atherogenic properties, downstream in the vasculature. We therefore propose a novel idea that diacerein may act to diminish IL-1-induced atherogenesis both indirectly via skin and directly on ECs in the vasculature. Interestingly, there is a recombinant, non-glycosylated antagonist of the human IL-1 receptor, anakinra. Although limited clinical data exists, one pilot study showed anakinra to have modest benefit in patients with psoriasis and psoriatic arthritis \[[@pone.0173981.ref069]\]. In conclusion, this study provides evidence that diacerein reverses the pro-atherogenic and pro-inflammatory gene regulation caused by IL-1 in ECs and KCs, potentially preventing progression of skin inflammation and inflammation-induced atherosclerosis. Diacerein may have an advantage over biologic therapies. Biologics like TNF-alpha inhibitors are proteins with a partial animal component and have the potential to induce an antibody response in patients, leading to the drug's ineffectiveness. Diacerein, being a small-molecule drug administered orally, has a substantially reduced tendency to induce such antibodies. Future investigation into clinical use of diacerein to benefit both the skin and vasculature by diminishing atherogenesis and inflammation, is warranted.

Methods {#sec017}
=======

Materials {#sec018}
---------

IL-1α, IL-1β, 10% fetal-bovine-serum growth medium for KCs, penicillin/streptomycin, sodium pyruvate, non-essential amino acids (Invitrogen, Carlsbad, CA), culture medium and cell-lysis kit for ECs (Cell Applications, San Diego, CA), RNA isolation kit and protocol, First strand kit, RT^2^ SYBR Green ROX qPCR master mix, Human Inflammatory Response and Autoimmunity 384HT PCR-arrays, Human Atherosclerosis 96-well PCR-arrays (Qiagen, Valencia, CA) ([Table 5](#pone.0173981.t005){ref-type="table"}) and diacerein (lyophilized powder dissolved in 50% DMSO and filtered water) (Sigma-Aldrich, St. Louis, MO) were used.

10.1371/journal.pone.0173981.t005

###### List of 84 atherosclerosis-related genes and 370 inflammation-related genes tested through PCR array

![](pone.0173981.t005){#pone.0173981.t005g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **84 atherosclerosis-related genes tested**\
  **    •  Response to Stress:**\
          ○  CCL2, CCL5, CCR1, CCR2, IL1R1, IL1R2, ITGB2, NFKB1, NOS3, SELE, SPP1, TNF, APOE, CCL5, SOD1, CCL2, CCR2, CSF2, FN1, IL4, ITGB2, TNF, CCL5, IFNAR2, TNF, CCR1, CCR2, CTGF, FN1, PDGFB, TNF, VWF, IFNG, PPARG, VEGFA.\
  **    •  Apoptosis:**\
          ○  Anti-apoptosis: BCL2, BCL2A1, BCL2L1, BIRC3, CCL2, CFLAR, FAS (TNFRSF6), IL1A, IL2, NFKB1, SERPINB2, SPP1, TGFB1, TNF, TNFAIP3.\
          ○  Induction of Apoptosis: APOE, BAX, BID, CFLAR, FAS (TNFRSF6).\
          ○  Other Genes Related to Apoptosis: IL5, ITGB2.\
  **    •  Blood Coagulation and Circulation:**\
          ○  Blood Coagulation: FGA, ITGA2, LPA, SERPINE1.\
          ○  Circulation: APOA1, APOB, APOE, COL3A1, ELN, ENG, LPA, LPL, NPY.\
          ○  Platelet Activation: PDGFA, PDGFB, PDGFRB, VWF.\
          ○  Regulation of Blood Pressure: ACE, FGA.\
  **    •  Adhesion Molecules:**\
          ○  Cell-cell Adhesion: CD44, CDH5, ICAM1, ITGB2, SELE, SELL, TNF, VCAM1, VEGFA.\
          ○  Cell-matrix Adhesion: CD44, ITGA2, ITGA5, ITGAX, ITGB2, SPP1.\
          ○  Other Genes Involved in Adhesion: CCL2, CCL5, CCR1, CTGF, ELN, ENG, FN1, LAMA1, SELPLG, THBS4, TNC, VWF.\
  **    •  Extracellular Molecules:**\
          ○  ECM Protease Inhibitors: LPA, SERPINB2, SERPINE1.\
          ○  ECM Proteases: ACE, MMP1, MMP3.\
          ○  Extracellular Matrix (ECM) Structural Constituents: COL3A1, ELN, FN1.\
          ○  Other Extracellular Molecules: ADFP, APOA1, APOB, APOE, CCL2, CCL5, CSF2, CTGF, FGA, FGF2, HBEGF (DTR), IFNAR2, IFNG, IL1A, IL2, IL3, IL4, IL5, LAMA1, LIF, LPL, NPY, PDGFA, PDGFB, SPP1, THBS4, TNC, VEGFA, VWF.\
  **    •  Lipid Transport and Metabolism:**\
          ○  Cholesterol Metabolism: ABCA1, APOA1, APOB, APOE, IL4, LDLR.\
          ○  Fatty Acid Metabolism: FABP3, LPL, PPARA, PTGS1.\
          ○  Lipid Transport: ABCA1, APOA1, APOB, APOE, FABP3, LDLR, LPA, LPL, MSR1.\
          ○  Lipoprotein Metabolism: APOA1, APOE, LDLR, LPL.\
          ○  Steroid Metabolism: NR1H3, PPARA, PPARD, PPARG, RXRA.\
          ○  Other Genes Related to Lipid Metabolism: PLIN2, APOE, LPA.\
  **    •  Cell Growth and Proliferation:**\
          ○  Growth Factors and Receptors: CSF2, KDR, PDGFRB, SPP1.\
          ○  Negative Regulation of Cell Proliferation: BCL2, FABP3, IL1A.\
          ○  Positive Regulation of Cell Proliferation: CSF1, FGA, FGF2, HBEGF (DTR), IL2, IL3, IL5, LIF, VEGFA.\
          ○  Regulation of the Cell Cycle: FGF2, IL1A, PDGFA, PDGFB, TGFB1, TGFB2, VEGFA.\
          ○  Other Genes Involved in Cell Growth and Proliferation: CTGF, ELN, IFNG, IL4, NPY.\
  **    •  Transcription Regulators:**\
          ○  Nuclear Receptors: NR1H3, PPARA, PPARD, PPARG, RXRA.\
          ○  Other Transcription Regulators: EGR1, KLF2, NFKB1, TNF, TNFAIP3.

  **370 inflammation-related genes tested**\
  **    •  Cytokines:**\
          ○  Chemokines[:]{.ul} CCL1, CCL11, CCL13, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL7, CCL8, CKLF, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL2, CXCL3, CXCL5, CXCL6, CXCL9, CYP26B1, PF4V1, PPBP, PXMP2, XCL1.\
          ○  Interleukins[:]{.ul} IL10, IL11, IL12A, IL12B, IL13, IL15, IL16, IL17A, IL17B, IL17C, IL17D, IL17F, IL18, IL19, IL1A, IL1B, IL1F10, IL36RN, IL36A, IL37, IL36B, IL36G, IL1RN, IL2, IL20, IL21, IL22, IL23A, IL24, IL25 (IL17E), IL26, IL27, IFNL1, IL3, IL32, IL4, IL5, IL6, IL7, IL8, IL9.\
          ○  Other Cytokines: AREG, BMP1, BMP2, BMP3, BMP7, CD40LG (TNFSF5), CD70 (TNFSF7), CLC, CMTM1 (CKLFSF1), CMTM2 (CKLFSF2), CSF1 (MCSF), CSF2 (GM-CSF), CSF3 (GCSF), CTF1, CXCL16, EBI3, EDA, EPO, FASLG, FGF1, FGF10, FGF12, FGF2 (bFGF), FGF7, FIGF, FLT3LG, GDF2, GDF3, GDF5, GDF6, GDF9, GLMN, GPI, GREM1, GREM2, GRN, IFNA1, IFNA14, IFNA2, IFNA4, IFNA8, IFNB1, IFNE, IFNG, IFNK, IFNW1, IFNWP2, IK, INHA, INHBA, INHBB, KITLG, LEFTY1, LEFTY2, LIF, LTA, LTB, MDK, MIF, MSTN, NODAL, OSM, NAMPT, PDGFA, PDGFB, PRL, PTN, SECTM1, SLURP1, SOCS2, SPP1, THPO, TNF, TNFRSF11B, TNFSF10, TNFSF11, TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF18, TNFSF4, TNFSF8, TNFSF9, TRAP1, TYMP, VEGFA, VEGFB, YARS.\
  **    •  Cytokine Receptors:**\
          ○  Chemokine Receptors: CCR1, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, ACKR4, CCRL2, CX3CR1, CXCR1 (IL8RA), CXCR2 (IL8RB), CXCR3, CXCR4, CXCR5, CXCR6, XCR1.\
          ○  Interleukin Receptors: IL10RA, IL10RB, IL11RA, IL12B, IL12RB1, IL12RB2, IL13RA1, IL13RA2, IL15RA, IL17RA, IL17RB, IL18R1, IL1R1, IL1R2, IL1RAP, IL1RAPL2, IL1RL1, IL1RL2, IL20RA, IL21R, IL22RA1, IL22RA2, IFNLR1, IL2RA, IL2RB, IL2RG, IL31RA, IL3RA, IL4R, IL5RA, IL6R, IL6ST, IL7R, IL9R\
          ○  Other Cytokine Receptors: CNTFR, CSF2RA, CSF2RB, CSF3R, EBI3, EPOR, F3, GFRA1, GFRA2, GHR, IFNAR1, IFNAR2, IFNGR1, IFNGR2, LEPR, LIFR, MPL, OSMR, PRLR, TTN.\
  **    •  Cytokine Metabolism:**\
          ○  APOA2, AZU1, CD27 (TNFRSF7), CD28, CD4, CD86, EBI3, GLMN, IL10, IL12B, IL17F, IL18, IL21, IL27, IL4, INHA, INHBA, INHBB, IRF4, NLRP12, PRG3, S100B, SFTPD, SIGIRR, TLR1, TLR3, TLR4, TLR6, TNFSF15.\
  **    •  Cytokine Production:**\
          ○  APOA2, AZU1, CD27 (TNFRSF7), CD28, CD4, CD86, EBI3, GLMN, IL10, IL12B, IL17F, IL18, IL21, IL27, IL4, INHA, INHBA, INHBB, INS, IRF4, NFAM1, NLRP12, NOX5, PRG3, S100B, SFTPD, SIGIRR, TLR1, TLR3, TLR4, TLR6.\
  **    •  Cytokine-Cytokine Receptor Interaction:**\
          ○  CCR1, CD40 (TNFRSF5), CXCR3, IL18RAP, IL23R, XCR1.\
  **    •  Acute-Phase Response:**\
          ○  AHSG, APCS, APOL2, CEBPB, CRP, F2, F8, FN1, IL22, IL6, INS, ITIH4, LBP, REG3A (PAP), REG3G, SAA4, SERPINA1, SERPINA3, SERPINF2, SIGIRR, STAT3.\
  **    •  Inflammatory Response:**\
          ○  AIMP1, ADORA1, AIF1, APOA2, APOL3, AZU1, BCL6, BLNK, C3, C3AR1, CCL1, CCL11, CCL13, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL3, CCL4, CCL5, CCL7, CCL8, CCR1, CCR2, CCR3, CCR4, CCR7, CD14, CD180, CD40, CD40LG, CD74, CD97, CKLF, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL3, CXCL5, CXCL6, CXCL9, CXCR1 (IL8RA), CXCR2 (IL8RB), CYBB, DOCK2, EPHX2, F11R, FOS, FPR1, GPR68, HDAC4, HDAC5, HDAC7, HDAC9, HRH1, CARD18, IFNA2, IL10, IL10RB, IL13, IL17A, IL17B, IL17C, IL17D, IL17F, IL18RAP, IL1A, IL1B, IL1F10, IL36RN, IL36A, IL1R1, IL1RAP, IL1RN, IL20, IL25 (IL17E), IL31RA, IL5, IL8, IL9, IRF7, ITGB2, KNG1, LTB4R, LY75, LY86, LY96, MEFV, MGLL, MIF, MMP25, MYD88, NCR3, NFAM1, NFATC3, NFATC4, NFE2L1, NFKB1, NFRKB, NFX1, NLRP12, NMI, NOS2 (iNOS), NR3C1, OLR1, PARP4, PGLYRP1, PLA2G2D, PLA2G7, PRDX5, PREX1, PRG2, PRG3, PROCR, PROK2, PTAFR, PTGS2 (COX2), PTPRA, PTX3, RIPK2, S100A12, S100A8, SCUBE1, SELE, SFTPD, SIGLEC1 (SN), SPACA3, SPP1, STAB1, SYK, TACR1, TIRAP, TLR1, TLR10, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TNF, TNFAIP6, TOLLIP, TPST1, VPS45, XCR1.\
  **    •  Humoral Immune Response:**\
          ○  BLNK, C3, CCL16, CCL18, CCL2, CCL20, CCL22, CCL3, CCL7, CCR2, CCR6, CCR7, CCRL2, CD27 (TNFRSF7), CD28, CD40, CD74, CD86, CLC, CSF2RB, CXCR3, CYBB, EBI3, GPI, IL10, IL12A, IL12B, IL12RB1, IL13, IL18, IL1B, IL2, IL26, IL4, IL6, IL7, IL7R, IRF4, ITGB2, LY86, LY96, NFKB1, PTAFR, S100B, SFTPD, XCL1, XCR1.\
  **    •  Other Genes Involved in Immune Response:**\
          ○  CAST, ERBB2, ERBB2IP, MUC4, SDCBP, SLCO1A2, SPRED1, SRGAP1.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture and treatment {#sec019}
--------------------------

Human primary keratinocytes (Invitrogen, Carlsbad, CA, catalog\# C-005-25P-A) and human primary coronary artery endothelial cells (Cell Applications Inc., San Diego, CA, catalog\# 300K-05a) were cultured under standard conditions (humidified atmosphere, 5% CO2 at 37°C) in growth medium supplemented with sodium pyruvate, non-essential amino acids and penicillin/streptomycin; media were replaced every 48 hours. KCs were differentiated from basal to mature keratinocytes by placing into a higher-calcium medium for 48--72 hours. At 80% confluence, cells were treated for 24 hours either with IL-1α or IL-1β only (25ng/ml IL-1α or 10ng/ml IL-1β in KCs and 10ng/ml IL-1α or 10ng/ml IL-1β in ECs), IL-1α or IL-1β combined with diacerein (diacerein concentrations: 10μM in KCs and 15μM in ECs with IL-1α; 20μM in KCs and 50μM in ECs with IL-1β--these concentrations were established using a dose-response curve prior to the experiment), or vehicle (DMSO). After 24 hours, cell culture supernatant was collected and stored at -80°C, and cells were washed with ice-cold phosphate-buffered-saline and frozen at -80°C until RNA isolation.

RNA isolation and real-time polymerase chain reaction (PCR) analysis {#sec020}
--------------------------------------------------------------------

Total RNA from KCs and ECs were isolated using Trizol reagent per manufacturer's instructions. Reverse-transcription using First strand kit formed cDNA. Genes reported in the literature to be regulated by IL-1 and relevant to the pathogenesis of skin or vascular inflammation/atherosclerosis, were tested by real-time PCR using custom primers (Integrated DNA Technologies, Coralville, IA).

PCR-array {#sec021}
---------

Using KC and EC cDNA, PCR-arrays were used per manufacturer's instructions. 10μL of master mix with cDNA was loaded into each well, and PCR reaction was run (ViiA-7 PCR machine, Applied Biosystems, Waltham, MA). Cycling conditions used: 95°C (10 minutes), then 40 repeating cycles of 95°C (15 seconds) followed by 60°C (60 seconds). Experiments were repeated in triplicate using four biologic replicates. Raw data were analyzed by a web-based Array Analysis Software (Qiagen). Data was normalized using house-keeping genes (ACTB, B2M, GAPDH, HPRT1, RPLP0). We then identified genes that were at least 2-fold up- or down-regulated after addition of IL-1 and/or diacerein in comparison to control, with p-value\<0.05.

Enzyme linked immunosorbent assay (ELISA) {#sec022}
-----------------------------------------

ELISA-kits were purchased based on PCR-array result. Kit were used according to manufacturer's instructions. ELISA micro-plates were analyzed using Synergy HT Multi-Mode Microplate Reader (BioTek, Winooski, VT) per the kit protocol, usually 450nm.

For IL-1α-treated cells, CSF2 (Sigma-Aldrich), SELE (Sigma-Aldrich), IL-9 (Sigma-Aldrich), CXCR3 (MyBioSource.com, San Diego, CA), TGF-B2 (Abcam, Cambridge, MA) and ACE (Abcam) human ELISA-kits were used.

For IL-1β-treated cells, E-Selectin (Sigma-Aldrich), TNF-alpha (Invitrogen) CCL5 (Biomatic USCN Life Sciences Inc., Wuhan, Hubei, China) VCAM-1 (Sigma-Aldrich) and CSF2 (Sigma-Aldrich) human ELISA-kits were used.

Pan-caspase assay {#sec023}
-----------------

Pan-caspase assay was performed using CaspaTag™ Pan-Caspase In Situ Assay Kit (EMD Millipore, Billerica, MA) according to the manufacturer's instructions. Briefly, cells were seeded in 12-well plates and harvested 24 hours after treatment. Cells were trypsinized and centrifuged after trypsin inactivation. Next 90 μl of 1% charcoal-dextran-treated FBS was added into each tube with 3 μl of 30X FLICA to resuspend cells. Then cells were incubated for 1 hour at 37°C under 5% CO2. After a series of washes, cells were resuspended in PBS and counted. Absorbance using an excitation wavelength of 485 nm and an emission wavelength of 520 nm was read in a Tecan Infinite 200 Pro multimode reader (Tecan US Inc., Morrisville, NC).

Statistical analysis {#sec024}
--------------------

PCR-array raw data were analyzed as listed above. Other data reported in this study (ELISA, real-time PCR) are the mean of 4 biologic replicates +/- standard error of the mean and were analyzed by ANOVA with p-value \<0.05 taken as significant.

Supporting information {#sec025}
======================

###### This includes original PCR array data from endothelial cells.

(XLS)

###### 

Click here for additional data file.

###### This includes original PCR array data from keratinocytes.

(XLS)

###### 

Click here for additional data file.
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IL-1α

:   interleukin-1alpha

IL-1β

:   interleukin-1beta

EC

:   primary human coronary artery endothelial cell

KC

:   primary human keratinocyte

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: **Conceptualization:** LSC LB.**Formal analysis:** GCM HZ LB.**Funding acquisition:** LSC LB.**Investigation:** GCM HZ BM.**Methodology:** LSC LB.**Project administration:** LSC.**Resources:** LSC LB.**Supervision:** LSC.**Validation:** LB.**Visualization:** GCM HZ.**Writing -- original draft:** GCM HZ.**Writing -- review & editing:** GCM HZ LB LSC.
